跳转至内容
Merck
CN

5.00671

HDAC Inhibitor XVII

别名:

HDAC Inhibitor XVII, (E)-N-Hydroxy-4-methoxy-2-(biphenyl-4-yl)cinnamide, Histone Deacetylase Inhibitor XVII

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C22H19NO3
化学文摘社编号:
分子量:
345.39
UNSPSC Code:
12352200
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

assay

≥99% (HPLC)

form

powder

potency

27 nM IC50

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze, protect from light

color

light beige

solubility

DMSO: 100 mg/mL

Quality Level

General description

A cell-permeable N-hydroxycinnamide derivative that acts a highly potent and HDAC8-selective histone deacetylase inhibitor (IC50 = 27 nM), displaying much reduced potency against HDAC1/3 (IC50 = 3.0 µM) and little or no activity toward HDAC2/4/6/10/11 (IC50 >20 µM) or total HDAC activity in HeLa nuclear extract (IC50 >10 µM). Reported to exhibit antiproliferative activity toward human lung cancer cells CL1-5, H1299, and A549 (IC50 = 7.0, 7.2, and 7.9 µM, respectively), while being much less toxic to low HDAC8-expressing CL1-1 (IC50 >10 µM) or normal human lung IMR-90 (73% inhibition at 40 µM) cells.

Biochem/physiol Actions

Cell permeable: yes
Primary Target
HDAC8 selective
Reversible: yes

Packaging

Packaged under inert gas

Preparation Note

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Other Notes

Huang, W. J., et al. 2012. ChemMedChem.7, 1815.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

相关内容

Cancer is a complex disease manifestation. At its core, it remains a disease of abnormal cellular proliferation and inappropriate gene expression. In the early days, carcinogenesis was viewed simply as resulting from a collection of genetic mutations that altered the gene expression of key oncogenic genes or tumor suppressor genes leading to uncontrolled growth and disease (Virani, S et al 2012). Today, however, research is showing that carcinogenesis results from the successive accumulation of heritable genetic and epigenetic changes. Moreover, the success in how we predict, treat and overcome cancer will likely involve not only understanding the consequences of direct genetic changes that can cause cancer, but also how the epigenetic and environmental changes cause cancer (Johnson C et al 2015; Waldmann T et al 2013). Epigenetics is the study of heritable gene expression as it relates to changes in DNA structure that are not tied to changes in DNA sequence but, instead, are tied to how the nucleic acid material is read or processed via the myriad of protein-protein, protein-nucleic acid, and nucleic acid-nucleic acid interactions that ultimately manifest themselves into a specific expression phenotype (Ngai SC et al 2012, Johnson C et al 2015). This review will discuss some of the principal aspects of epigenetic research and how they relate to our current understanding of carcinogenesis. Because epigenetics affects phenotype and changes in epigenetics are thought to be key to environmental adaptability and thus may in fact be reversed or manipulated, understanding the integration of experimental and epidemiologic science surrounding cancer and its many manifestations should lead to more effective cancer prognostics as well as treatments (Virani S et al 2012).

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持